Search Results
Showing Results for non-alcoholic steatohepatitis
Article Highlights This study aims to find an effective and affordable biomarker panel for early non-alcoholic fatty liver disease (NAFLD) detection in Indian women with morbid obesity, given the rising prevalence of NAFLD and limited accessibility of ultrasound sonography (USG) ...
Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as ...
Hepatic steatosis is the liver manifestation of metabolic syndrome and a common cause of chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) diagnosis relies on the presence of hepatic steatosis, defined as >5% fat accumulation in the liver, as observed ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1Â Closely linked to T2D is metabolic dysfunction-associated steatotic ...
There has been an exponential increase in the global prevalence of obesity over the past few decades because of adverse lifestyle choices, such as physical inactivity and overconsumption of macronutrients. The obesity pandemic has contributed to more than 50 different disorders ...
CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. We caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) ...
CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. In this touchENDOCRINOLOGY interview, we caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University ...
Liver conditions are often misunderstood, mischaracterized and stigmatized, which results in under-diagnosis, under-treatment and unnecessarily poor outcomes worldwide. The Global Liver Institute (GLI) "Liver Health is Public Health" initiative aims to respond to this unmet need and educate the public ...
International NASH Day (NASH Day) takes place on the 8th June 2023. It is a public education campaign launched in June 2018 to raise visibility and urgency around fatty liver disease and its more advanced form, nonalcoholic steatohepatitis (NASH), which affects more ...
Welcome to the latest edition of touchREVIEWS in Endocrinology. In this edition we feature a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We start with ...
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of fatty liver diseases, including non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).1 NAFLD is associated with metabolic disorders, including obesity, hypertension, dyslipidaemia, type 2 diabetes mellitus (T2DM), hypothyroidism and metabolic syndrome.2 ...
Polycystic ovary syndrome (PCOS) is a very common disease, with an incidence of 5−21% in women during their fertile life (18–45 years of age) worldwide.1 PCOS is clinically diagnosed when two of the three 2003 Rotterdam consensus criteria are met: (i) chronic anovulation ...
Welcome to the latest edition of touchREVIEWS in Endocrinology, which includes a broad range of articles selected for their evaluation of current practices and research that directly affect endocrinologists as well as being of interest to the wider biomedical community. ...
Non-alcoholic fatty liver disease (NAFLD), which impacts an estimated 25% of the world’s adult population,1–3 is the principal cause of chronic liver disease globally. NAFLD as a whole represents a pathological spectrum of liver injury, spanning from simple steatosis to ...
Nutrient-stimulated gastric inhibitory polypeptide (GIP) (known as either gastric inhibitory polypeptide or glucose-dependent insulinotropic polypeptide) or glucagon-like peptide (GLP-1), are secreted by K and L cells, respectively, in the upper segment of the small intestine and throughout the intestine. For ...
Obesity – a chronic, relapsing, progressive disease that is defined by a body mass index (BMI) of ≥27.5 kg/m2 in Asian populations and ≥30.0 kg/m2 in all other populations – is an epidemic that has spread across the world.1 Recent data from ...
Nonalcoholic steatohepatitis (NASH) has a relatively short history as a recognized health condition. The terminology for NASH and its precursor nonalcoholic fatty liver disease (NAFLD) date back to only the 1980s1. As a young disease, the stakeholders from throughout the ...
To view the full Press Release, please click here. (Washington, DC, Wednesday, March 9, 2022)—Today, Global Liver Institute (GLI) is proud to launch the final NASH Externally-Led Patient Focused Drug Development Meeting Outcome Report. On November 4th 2021, Global Liver Institute led ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
